Compare Eli Lilly And Co (LLY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Wix.Com Ltd — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Wix.Com Ltd trades at $76.35 (market cap $3.11B). The key difference: Eli Lilly And Co is far larger — about 334.4× Wix.Com Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Wix.Com Ltd for 62 Days on average.
| LLY | WIX | |
|---|---|---|
Market Cap | $1.04T | $3.11B |
Volume | 3,064,878 | 809,286 |
Sector | Health | Technology |
52-Week High | $1.28K | $145.54 |
52-Week Low | $799.57 | $40.43 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $1.09T | $4.19B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Wix.com (WIX) trades at $76.56, up 4.92% in the last 24 hours, with technical indicators showing a neutral to bullish bias. Revenue growth is robust, reaching $1.99B in 2025, but profitability is inconsistent, with a net income margin of -8.19% in 2026. Analyst sentiment is positive, with a consensus buy rating and a $77 price target, though recent class action lawsuits add caution.
The outlook for WIX hinges on sustaining revenue growth while improving profitability. Risks include legal challenges and volatile earnings, but strong analyst support and a solid market position offer potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
